David P.  Meeker net worth and biography

David Meeker Biography and Net Worth

Dr. David Meeker, a member of Rhythm’s Board of Directors since 2015 and Chairman of the Board since 2017, was appointed President and Chief Executive Officer of the Company in July 2020. Most recently, he served as President and CEO of KSQ Therapeutics for approximately three years. Previously, David was the Executive Vice President and Head of Sanofi Genzyme, the specialty-care global business unit of Sanofi that focused on rare diseases, multiple sclerosis, oncology and immunology. He joined Genzyme in 1994 as Medical Director and, over the course of his tenure, served the company as Vice President of Medical Affairs, Chief Operating Officer, and Chief Executive Officer. He led Genzyme’s commercial organization and global market access functions and managed the launch of several treatments for rare genetic diseases, including Aldurazyme®, Fabrazyme® and Myozyme®. Prior to his tenure with Genzyme, David was Director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and an Assistant Professor of Medicine at Ohio State University. Dr. Meeker earned his M.D. from the University of Vermont Medical School and completed the advanced management program at Harvard Business School.

What is David P. Meeker's net worth?

The estimated net worth of David P. Meeker is at least $20.92 million as of August 27th, 2024. Dr. Meeker owns 352,489 shares of Rhythm Pharmaceuticals stock worth more than $20,923,747 as of November 21st. This net worth estimate does not reflect any other assets that Dr. Meeker may own. Additionally, Dr. Meeker receives a salary of $1,350,000.00 as CEO at Rhythm Pharmaceuticals. Learn More about David P. Meeker's net worth.

How old is David P. Meeker?

Dr. Meeker is currently 70 years old. There are 6 older executives and no younger executives at Rhythm Pharmaceuticals. Learn More on David P. Meeker's age.

What is David P. Meeker's salary?

As the CEO of Rhythm Pharmaceuticals, Inc., Dr. Meeker earns $1,350,000.00 per year. Learn More on David P. Meeker's salary.

How do I contact David P. Meeker?

The corporate mailing address for Dr. Meeker and other Rhythm Pharmaceuticals executives is 222 BERKELEY STREET 12TH FLOOR, BOSTON MA, 02116. Rhythm Pharmaceuticals can also be reached via phone at (857) 264-4280 and via email at [email protected]. Learn More on David P. Meeker's contact information.

Has David P. Meeker been buying or selling shares of Rhythm Pharmaceuticals?

David P. Meeker has not been actively trading shares of Rhythm Pharmaceuticals during the past quarter. Most recently, David P. Meeker sold 45,494 shares of the business's stock in a transaction on Tuesday, March 19th. The shares were sold at an average price of $39.22, for a transaction totalling $1,784,274.68. Following the completion of the sale, the chief executive officer now directly owns 174,605 shares of the company's stock, valued at $6,848,008.10. Learn More on David P. Meeker's trading history.

Who are Rhythm Pharmaceuticals' active insiders?

Rhythm Pharmaceuticals' insider roster includes Pamela Cramer (Insider), Jennifer Good (Director), Jennifer Lee (EVP), Yann Mazabraud (EVP), David Meeker (CEO), Joseph Shulman (Insider), Hunter Smith (CFO), and Lynn Tetrault (Director). Learn More on Rhythm Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Rhythm Pharmaceuticals?

In the last twelve months, insiders at the sold shares 26 times. They sold a total of 410,931 shares worth more than $20,497,452.48. The most recent insider tranaction occured on November, 11th when EVP Jennifer Kayden Lee sold 66,861 shares worth more than $4,434,890.13. Insiders at Rhythm Pharmaceuticals own 5.6% of the company. Learn More about insider trades at Rhythm Pharmaceuticals.

Information on this page was last updated on 11/11/2024.

David P. Meeker Insider Trading History at Rhythm Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/19/2024Sell45,494$39.22$1,784,274.68174,605View SEC Filing Icon  
3/30/2021Buy10,000$20.17$201,700.00111,335View SEC Filing Icon  
10/10/2017Buy25,000$17.00$425,000.00View SEC Filing Icon  
See Full Table

David P. Meeker Buying and Selling Activity at Rhythm Pharmaceuticals

This chart shows David P Meeker's buying and selling at Rhythm Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Rhythm Pharmaceuticals Company Overview

Rhythm Pharmaceuticals logo
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $60.11
Low: $58.02
High: $60.16

50 Day Range

MA: $52.94
Low: $47.20
High: $67.33

2 Week Range

Now: $60.11
Low: $31.52
High: $68.58

Volume

74,922 shs

Average Volume

546,902 shs

Market Capitalization

$3.69 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.09